Design and synthesis of NAD(P)H: Quinone oxidoreductase (NQO1)-activated prodrugs of 23-hydroxybetulinic acid with enhanced antitumor properties.

[1]  W. Denny.  Nitroaromatic Hypoxia-Activated Prodrugs for Cancer Therapy , 2022, Pharmaceuticals.

[2]  Xiaojuan Yang,et al.  Research advances in NQO1-responsive prodrugs and nanocarriers for cancer treatment. , 2022, Future medicinal chemistry.

[3]  Nanxin Liu,et al.  The application of prodrug-based drug delivery strategy in anticancer drugs. , 2021, Current topics in medicinal chemistry.

[4]  Yue Li,et al.  NQO1-selective activated prodrugs of combretastatin A-4: Synthesis and biological evaluation. , 2020, Bioorganic chemistry.

[5]  Kwangmeyung Kim,et al.  Recent trends in in-situ enzyme-activatable prodrugs for targeted cancer therapy. , 2020, Bioconjugate chemistry.

[6]  Shengtao Xu,et al.  Synthesis, biological evaluation and mechanism studies of C-23 modified 23-hydroxybetulinic acid derivatives as anticancer agents. , 2019, European journal of medicinal chemistry.

[7]  D. Boothman,et al.  NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance , 2019, Nature Communications.

[8]  Wei Song,et al.  NQO1-Selective Activated Prodrug of Triptolide: Synthesis and Antihepatocellular Carcinoma Activity Evaluation. , 2018, ACS medicinal chemistry letters.

[9]  W. Ye,et al.  Synthesis, Biological Evaluation of Fluorescent 23-Hydroxybetulinic Acid Probes, and Their Cellular Localization Studies. , 2018, ACS medicinal chemistry letters.

[10]  Guangyu Wang,et al.  Design, synthesis, and biological evaluation of NAD(P)H: Quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation. , 2017, European journal of medicinal chemistry.

[11]  W. Ye,et al.  Synthesis and Biological Evaluation of Oxygen‐containing Heterocyclic Ring‐fused 23‐Hydroxybetulinic Acid Derivatives as Antitumor Agents , 2015, Chemical biology & drug design.

[12]  Zhe-Sheng Chen,et al.  B4G2 Induces Mitochondrial Apoptosis by the ROS-Mediated Opening of Ca2+-Dependent Permeability Transition Pores , 2015, Cellular Physiology and Biochemistry.

[13]  W. Ye,et al.  Design, synthesis and antitumor activity of triterpenoid pyrazine derivatives from 23-hydroxybetulinic acid. , 2015, European journal of medicinal chemistry.

[14]  W. Gao,et al.  Synthesis of heterocycle-modified betulinic acid derivatives as antitumor agents. , 2015, European journal of medicinal chemistry.

[15]  Jinming Gao,et al.  Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[16]  W. Ye,et al.  Synthesis, in vitro and in vivo antitumor activity of pyrazole-fused 23-hydroxybetulinic acid derivatives. , 2015, Bioorganic & medicinal chemistry letters.

[17]  Xiukun Lin,et al.  Cytotoxicity of the compounds isolated from Pulsatilla chinensis saponins and apoptosis induced by 23-hydroxybetulinic acid , 2015, Pharmaceutical biology.

[18]  W. Ye,et al.  Synthesis and antitumor activity of novel 3-oxo-23-hydroxybetulinic acid derivatives. , 2014, European journal of medicinal chemistry.

[19]  K. Sano,et al.  Synthesis and in vitro evaluation of radioiodinated indolequinones targeting NAD(P)H: quinone oxidoreductase 1 for internal radiation therapy. , 2014, Bioorganic & medicinal chemistry.

[20]  R. Olsson,et al.  Bexarotene prodrugs: targeting through cleavage by NQO1 (DT-diaphorase). , 2014, Bioorganic & medicinal chemistry letters.

[21]  Richard W. Kriwacki,et al.  Many players in BCL-2 family affairs. , 2014, Trends in biochemical sciences.

[22]  C. Moody,et al.  Benzofuran-, benzothiophene-, indazole- and benzisoxazole-quinones: excellent substrates for NAD(P)H:quinone oxidoreductase 1. , 2013, Bioorganic & medicinal chemistry.

[23]  H. Chakrapani,et al.  INDQ/NO, a bioreductively activated nitric oxide prodrug. , 2013, Organic letters.

[24]  X. Jiang,et al.  Clearing the final hurdles to mitochondrial apoptosis: regulation post cytochrome C release. , 2012, Experimental oncology.

[25]  W. Ye,et al.  Synthesis and antiproliferative evaluation of 23-hydroxybetulinic acid derivatives. , 2011, European journal of medicinal chemistry.

[26]  W. Ye,et al.  23-Hydroxybetulinic acid from Pulsatilla chinensis (Bunge) Regel synergizes the antitumor activities of doxorubicin in vitro and in vivo. , 2010, Journal of ethnopharmacology.

[27]  Thommey P. Thomas,et al.  The synthesis of a c(RGDyK) targeted SN38 prodrug with an indolequinone structure for bioreductive drug release. , 2010, Organic Letters.

[28]  M. Hiraoka,et al.  Monitoring of biological one-electron reduction by (19)F NMR using hypoxia selective activation of an (19)F-labeled indolequinone derivative. , 2009, Journal of the American Chemical Society.

[29]  Thommey P. Thomas,et al.  Human plasma-mediated hypoxic activation of indolequinone-based naloxone pro-drugs. , 2009, Bioorganic & medicinal chemistry letters.

[30]  J. Thorson,et al.  Enhancing the divergent activities of betulinic acid via neoglycosylation. , 2009, Organic letters.

[31]  Luyong Zhang,et al.  Synthesis and cytotoxic activity of 17-carboxylic acid modified 23-hydroxy betulinic acid ester derivatives. , 2007, Bioorganic & medicinal chemistry letters.

[32]  J. K. C. Ho,et al.  Apoptotic activity of betulinic acid derivatives on murine melanoma B16 cell line. , 2004, European journal of pharmacology.

[33]  Z. Ji,et al.  23-Hydroxybetulinic acid-mediated apoptosis is accompanied by decreases in bcl-2 expression and telomerase activity in HL-60 Cells. , 2002, Life sciences.

[34]  R. Borch,et al.  Design, synthesis, and biological evaluation of indolequinone phosphoramidate prodrugs targeted to DT-diaphorase. , 2002, Journal of medicinal chemistry.

[35]  G. Adams,et al.  Indolequinone antitumor agents: reductive activation and elimination from (5-methoxy-1-methyl-4,7-dioxoindol-3-yl)methyl derivatives and hypoxia-selective cytotoxicity in vitro. , 1998, Journal of medicinal chemistry.

[36]  W. Ye,et al.  Triterpenoids from Pulsatilla chinensis. , 1996, Phytochemistry.